DA approves onychomycosis topical new drug Jublia

Canada's Valeant Pharmaceuticals announced on June 9 that the anti-fungal drug Jublia (efinaconazole, 10% topical solution) of its North American subsidiary Valeant has been approved by the FDA for the treatment of onychomycosis, the first external use of the drug. Trizole antifungal drugs. Previously, Jublia was approved by Health Canada in November 2013. Valeant plans to launch the drug in the United States and Canada in the third quarter of 2014. Jublia’s peak sales in the United States are expected to be between $380 million and $800 million.

Onychomycosis is a common name for infectious diseases that occur on human nails. It is caused by a large group of microbial infections known as pathogenic fungi. The disease is currently undertreated, largely because Limitations of existing therapeutic drugs (http://). At present, the effect provided by over-the-counter or prescription external medicines is very limited. At the same time, it often requires frequent debridement, or scraping, cutting or removing nails. Prescription oral medications are very limited due to drug interactions and serious safety issues.

About Jublia (efinaconazole, 10% topical solution):

Jublia is the first triazole antifungal drug for topical use. It was developed for the treatment of local distal lateral parathyroid fungus (DLSO). This is the most common type of onychomycosis. The pathogenic bacteria first invade the distal armor. A nail bed, under the nail bed hyperplasia, thickening, the deck can become white, brown to grayish brown, uneven surface, loss of luster, lack of deck, crisp.

Jublia is a topical solution that is applied with a unique built-in dose-controlled nail brush that can dry quickly without removing excess medication without having to worry about systemic side effects such as drug interactions or acute liver injury .